193 related articles for article (PubMed ID: 31415187)
1. Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability.
Caverly LJ; Lu J; Carmody LA; Kalikin LM; Shedden K; Opron K; Azar M; Cahalan S; Foster B; VanDevanter DR; Simon RH; LiPuma JJ
Ann Am Thorac Soc; 2019 Dec; 16(12):1534-1542. PubMed ID: 31415187
[No Abstract] [Full Text] [Related]
2. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations.
Fodor AA; Klem ER; Gilpin DF; Elborn JS; Boucher RC; Tunney MM; Wolfgang MC
PLoS One; 2012; 7(9):e45001. PubMed ID: 23049765
[TBL] [Abstract][Full Text] [Related]
3. The metabolic footprint of the airway bacterial community in cystic fibrosis.
Narayanamurthy V; Sweetnam JM; Denner DR; Chen LW; Naureckas ET; Laxman B; White SR
Microbiome; 2017 Jun; 5(1):67. PubMed ID: 28666467
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
[TBL] [Abstract][Full Text] [Related]
5. Fungal and Bacterial Diversity of Airway Microbiota in Adults with Cystic Fibrosis: Concordance Between Conventional Methods and Ultra-Deep Sequencing, and Their Practical use in the Clinical Laboratory.
Botterel F; Angebault C; Cabaret O; Stressmann FA; Costa JM; Wallet F; Wallaert B; Bruce K; Delhaes L
Mycopathologia; 2018 Feb; 183(1):171-183. PubMed ID: 28766039
[TBL] [Abstract][Full Text] [Related]
6. Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis.
Carmody LA; Kalikin LM; VanDevanter DR; Li G; Opron K; Simon RH; Caverly LJ; LiPuma JJ
J Cyst Fibros; 2022 Sep; 21(5):766-768. PubMed ID: 35667975
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.
Peleg AY; Choo JM; Langan KM; Edgeworth D; Keating D; Wilson J; Rogers GB; Kotsimbos T
J Cyst Fibros; 2018 Jan; 17(1):50-56. PubMed ID: 29042177
[TBL] [Abstract][Full Text] [Related]
8. Divergence of bacterial communities in the lower airways of CF patients in early childhood.
O'Connor JB; Mottlowitz MM; Wagner BD; Boyne KL; Stevens MJ; Robertson CE; Harris JK; Laguna TA
PLoS One; 2021; 16(10):e0257838. PubMed ID: 34613995
[TBL] [Abstract][Full Text] [Related]
9. Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation.
Twomey KB; Alston M; An SQ; O'Connell OJ; McCarthy Y; Swarbreck D; Febrer M; Dow JM; Plant BJ; Ryan RP
PLoS One; 2013; 8(12):e82432. PubMed ID: 24358183
[TBL] [Abstract][Full Text] [Related]
10. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention.
Cuthbertson L; Rogers GB; Walker AW; Oliver A; Green LE; Daniels TW; Carroll MP; Parkhill J; Bruce KD; van der Gast CJ
ISME J; 2016 May; 10(5):1081-91. PubMed ID: 26555248
[TBL] [Abstract][Full Text] [Related]
11. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
[TBL] [Abstract][Full Text] [Related]
12. Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period.
Stokell JR; Gharaibeh RZ; Hamp TJ; Zapata MJ; Fodor AA; Steck TR
J Clin Microbiol; 2015 Jan; 53(1):237-47. PubMed ID: 25392361
[TBL] [Abstract][Full Text] [Related]
13. Individual Patterns of Complexity in Cystic Fibrosis Lung Microbiota, Including Predator Bacteria, over a 1-Year Period.
de Dios Caballero J; Vida R; Cobo M; Máiz L; Suárez L; Galeano J; Baquero F; Cantón R; Del Campo R
mBio; 2017 Sep; 8(5):. PubMed ID: 28951476
[TBL] [Abstract][Full Text] [Related]
14. The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation.
Carmody LA; Zhao J; Kalikin LM; LeBar W; Simon RH; Venkataraman A; Schmidt TM; Abdo Z; Schloss PD; LiPuma JJ
Microbiome; 2015; 3():12. PubMed ID: 25834733
[TBL] [Abstract][Full Text] [Related]
15. Mild Cystic Fibrosis Lung Disease Is Associated with Bacterial Community Stability.
Hampton TH; Thomas D; van der Gast C; O'Toole GA; Stanton BA
Microbiol Spectr; 2021 Sep; 9(1):e0002921. PubMed ID: 34232099
[TBL] [Abstract][Full Text] [Related]
16. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods.
Zemanick ET; Wagner BD; Robertson CE; Stevens MJ; Szefler SJ; Accurso FJ; Sagel SD; Harris JK
Ann Am Thorac Soc; 2015 Feb; 12(2):221-9. PubMed ID: 25474078
[TBL] [Abstract][Full Text] [Related]
17. Low Diversity and Instability of the Sinus Microbiota over Time in Adults with Cystic Fibrosis.
Armbruster CR; Li K; Kiedrowski MR; Zemke AC; Melvin JA; Moore J; Atteih S; Fitch AC; DuPont M; Manko CD; Weaver ML; Gaston JR; Alcorn JF; Morris A; Methé BA; Lee SE; Bomberger JM
Microbiol Spectr; 2022 Oct; 10(5):e0125122. PubMed ID: 36094193
[TBL] [Abstract][Full Text] [Related]
18. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
[No Abstract] [Full Text] [Related]
19. Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.
Sherrard LJ; Einarsson GG; Johnston E; O'Neill K; McIlreavey L; McGrath SJ; Gilpin DF; Downey DG; Reid A; McElvaney NG; Boucher RC; Muhlebach MS; Elborn JS; Tunney MM
J Cyst Fibros; 2019 Nov; 18(6):808-816. PubMed ID: 30905581
[TBL] [Abstract][Full Text] [Related]
20. Changes in microbiome diversity following beta-lactam antibiotic treatment are associated with therapeutic versus subtherapeutic antibiotic exposure in cystic fibrosis.
Hahn A; Fanous H; Jensen C; Chaney H; Sami I; Perez GF; Koumbourlis AC; Louie S; Bost JE; van den Anker JN; Freishtat RJ; Zemanick ET; Crandall KA
Sci Rep; 2019 Feb; 9(1):2534. PubMed ID: 30796252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
